Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
© The Author(s), 2016.The management of HER-2-positive breast cancer has improved significantly with the use of targeted agents to the HER-2 signaling pathway. Despite the improved survival achieved with the use of trastuzumab and chemotherapy in both the adjuvant and metastatic setting, patients ma...
| Main Author: | |
|---|---|
| Format: | Journal Article |
| Published: |
2016
|
| Online Access: | http://hdl.handle.net/20.500.11937/58342 |
| _version_ | 1848760235933564928 |
|---|---|
| author | Chan, Arlene |
| author_facet | Chan, Arlene |
| author_sort | Chan, Arlene |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © The Author(s), 2016.The management of HER-2-positive breast cancer has improved significantly with the use of targeted agents to the HER-2 signaling pathway. Despite the improved survival achieved with the use of trastuzumab and chemotherapy in both the adjuvant and metastatic setting, patients may still recur or progress; whilst preclinical data demonstrate that these cancer cells remain addicted to the HER-2 oncogene. Neratinib, an oral small molecule tyrosine-kinase inhibitor has efficacy in the metastatic and adjuvant setting of patients who have previously received trastuzumab-based treatment. Diarrhea, being a class effect of tyrosine-kinase inhibitor, is the most common side effect seen following neratinib administration, but recent data suggests that a prophylactic loperamide regimen can reduce the incidence of grade 3 diarrhea. Phase I through to III clinical trials of neratinib will be reviewed, with discussion of the postulated mechanism underlying diarrheal events and its management. |
| first_indexed | 2025-11-14T10:12:34Z |
| format | Journal Article |
| id | curtin-20.500.11937-58342 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:12:34Z |
| publishDate | 2016 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-583422017-11-24T05:46:26Z Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness Chan, Arlene © The Author(s), 2016.The management of HER-2-positive breast cancer has improved significantly with the use of targeted agents to the HER-2 signaling pathway. Despite the improved survival achieved with the use of trastuzumab and chemotherapy in both the adjuvant and metastatic setting, patients may still recur or progress; whilst preclinical data demonstrate that these cancer cells remain addicted to the HER-2 oncogene. Neratinib, an oral small molecule tyrosine-kinase inhibitor has efficacy in the metastatic and adjuvant setting of patients who have previously received trastuzumab-based treatment. Diarrhea, being a class effect of tyrosine-kinase inhibitor, is the most common side effect seen following neratinib administration, but recent data suggests that a prophylactic loperamide regimen can reduce the incidence of grade 3 diarrhea. Phase I through to III clinical trials of neratinib will be reviewed, with discussion of the postulated mechanism underlying diarrheal events and its management. 2016 Journal Article http://hdl.handle.net/20.500.11937/58342 10.1177/1758834016656494 unknown |
| spellingShingle | Chan, Arlene Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness |
| title | Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness |
| title_full | Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness |
| title_fullStr | Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness |
| title_full_unstemmed | Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness |
| title_short | Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness |
| title_sort | neratinib in her-2-positive breast cancer: results to date and clinical usefulness |
| url | http://hdl.handle.net/20.500.11937/58342 |